Аптеки жалуются на неправомерный отказ Beacon MFP в возмещении средств по программе 340B

Pharmacies continue to report to NCPA that Beacon MFP is inappropriately rejecting MFP refund claims due to 340B discounts and subsequently denying good faith inquiries (GFIs) by pharmacies that have no contract pharmacy relationships or have reasonable belief that a claim is not 340B-eligible. Pharmacies should access their 835 remittance advice or log into the Medicare Transaction Facilitator and review lines with Remittance Advice Remark Code (RARC) = N907, No refund because this claim has been identified as 340B-eligible with a ceiling price lower than the maximum fair price, to identify any rejected MFP refunds. The first step to correct this is to use the Beacon MFP GFI process. All of the manufacturers with an MFP drug in 2026 use Beacon MFP to handle GFIs from pharmacies, but you need to sign in or enroll to open a GFI. If using the Beacon MFP GFI process does not correct MFP refund payment, pharmacies should use CMS' dispute form in the MTF. It is critical that CMS receives disputes to have data it can use in compliance discussions with manufacturers. If you have questions for NCPA, email [email protected]. NCPA will have an expert on this issue on the exhibit floor of the 2026 NCPA Annual Convention in Kansas City, Mo., Oct. 3-6, in one of the new “How To” booths.